Navigation Links
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Date:10/15/2010

rogression for Teriflunomide 14mg

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced by 30% for the 14mg dose (p=0.02) and numerically reduced by 24% for the 7mg dose (p=0.08). Both doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) including serious adverse events or TEAEs leading to treatment discontinuation in the treatment vs. placebo arms.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/46556-Sanofi-Aventis-Teriflunomide/

"We are very pleased with the successful results of the TEMSO study which are an important step forward in multiple sclerosis clinical research," said Marc Cluzel, M.D., Ph.D., Executive Vice President, Research & Development, sanofi-aventis. "These exciting results with teriflunomide represent a new real hope to delivering an oral therapy to patients who live with this serious condition and are eager for new treatment options, and more convenient product forms in-line with our sanofi-aventis commitment to multiple sclerosis."

The results of the TEMSO trial are the first study findings from a large phase III clinical development program on teriflunomide. These results were presented today during the European Committee for Treatment and Research in M
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
2. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
3. Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System
4. Omeros Successfully Unlocks Orphan GPCRs
5. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
6. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
7. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
10. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
11. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 26, 2014 MNX Global Logistics, Medical ... renewed a multi-year contract providing time- and mission-critical ... spinal device company in the world. The precision ... is well suited to MNX,s main business competencies. ... involves a surgeon, surgical team and patient, who ...
(Date:8/26/2014)... , Aug. 26, 2014   Tocagen Inc. ... been named vice president, clinical development, and Mary ... operations. "As we advance Toca 511 ... expanding our clinical team with individuals who have deep ... activities," said Jamey Skillings , M.D., Chief Medical ...
(Date:8/26/2014)... , Aug. 26, 2014 Profil Institute ... organization (CRO) focused on diabetes and obesity, announced today a ... of more than 200 phase I – IIa clinical ... treatment of type 1 and type 2 diabetes.   ... research is what it represents for the public domain," ...
Breaking Medicine Technology:MNX Global Logistics renews multi-year contract with NuVasive, Inc. 2Tocagen Expands Clinical Development Team; 2Tocagen Expands Clinical Development Team; 3Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 2Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 3
... Animal Health has launched its second product in the ... milbemycin oxime), a broad-spectrum parasiticide that kills fleas and ... infestations, the prevention of heartworm disease and the treatment ... in dogs and puppies 8 weeks and older, and ...
... 17, 2011 SFA Marketing today announced a ... exclusively to working with medical device manufacturers. SFA ... more than 20 years experience working with clients ... (Logo: http://photos.prnewswire.com/prnh/20110117/NY30375LOGO) "In response ...
Cached Medicine Technology:Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:8/27/2014)... ALS Insights is a dedicated website created by ... a series of compelling interviews with people who have ... in searing honesty, about issues such as acceptance vs. ... happened in the final days and how the families ... dramatic increase in public awareness and financial support for ...
(Date:8/27/2014)... CT (PRWEB) August 27, 2014 ... cyclists of all abilities to go the distance this ... Alex’s Million Mile – Run. Walk. Ride. initiative, hosted ... and increase awareness of childhood cancer. September represents ... year’s Alex’s Million Mile, Inspira Marketing Group has teamed ...
(Date:8/27/2014)... Washington, D.C. (PRWEB) August 27, 2014 ... of Neurosurgery discusses the importance of time in correcting ... study focuses on a variety of anticoagulants and examines ... , According to the research, although anticoagulants have been ... stroke and systemic embolism, they are also known to ...
(Date:8/27/2014)... August 27, 2014 In My Solitude, a ... Collection” to provide a growing number of women from college ... for goal setting and relaxing at the same time. , ... uses scent memory and visualization to help women stay focused ... each time they light a candle and enjoy the fragrance. ...
(Date:8/27/2014)... 27, 2014 Janice Holly Booth ... when no-one would join her on an adventure outing to ... extreme sport involving ropes, harnesses and rappelling into mysterious, dark ... solo travel but definitely not my last,” she says. “I ... pushed me to the edge, and experienced first-hand the kind ...
Breaking Medicine News(10 mins):Health News:ALS Insights Launched as Web Resource of Interviews and Information 2Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 2Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 3Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:Best-selling Author Janice Holly Booth Offers Tips to Navigating Fear and Living a Fuller Life 2
... WEST LAFAYETTE, Ind. - A Purdue University research team ... antimicrobial agent as needed for extending the shelf life ... Yuan Yao, an assistant professor of food science, altered ... called phytoglycogen, which led to the creation of several ...
... HealthDay Reporter , MONDAY, Dec. 6 (HealthDay News) -- ... birth had a higher risk of behavior problems by their ... the devices, a new study of nearly 29,000 children suggests. ... of 13,000 children conducted by the same U.S. researchers. And ...
... too early are at an increased risk of death, ... Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100349.pdf ... that describes the flow rate of fluid going through ... Current guidelines in the United States place more emphasis ...
... (LSHTM) has contributed to a study showing that a low ... The study is published in today,s Lancet . ... Peter Rothwell in Oxford, and is based on an overview ... concerned with reducing heart attacks, but have also gathered information ...
... HealthDay Reporter , MONDAY, Dec. 6 (HealthDay News) -- ... to sex, according to an Australian study. The researchers found ... at least once a year -- including about 1 in 10 ... who are sexually active say they,d love to be having more ...
... the American Society of Hematology (ASH) annual meeting, investigators at ... why chronic lymphocytic leukemia (CLL) tends to recur in the ... bloodstream by chemotherapy. Their findings will be reported during in ... in room 315 of the Orange County Convention Center. ...
Cached Medicine News:Health News:Nanoparticle gives antimicrobial ability to fight Listeria longer 2Health News:Could Cell Phones Raise Odds for Behavioral Woes in Kids? 2Health News:Could Cell Phones Raise Odds for Behavioral Woes in Kids? 3Health News:Could Cell Phones Raise Odds for Behavioral Woes in Kids? 4Health News:Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent 2Health News:Many Men Over 75 Still Sexually Active: Study 2Health News:Many Men Over 75 Still Sexually Active: Study 3Health News:Study identifies drug resistance of CLL in bone marrow and lymph nodes 2
Simple straight stem design for the low-demand patient....
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
The P.S.L. stem is manufactured from cobalt chrome and is available with or without porous coating to give the surgeon the option of utilizing either the cementless of cemented technique at his or he...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products: